Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -105% Improvement Relative Risk c19hcq.org De Luna et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 150 patients in Dominican Republic Study underpowered to detect differences De Luna et al., medRxiv, doi:10.1101/2020.12.11.20247437 Favors HCQ Favors control
Clinical and Demographic Characteristics of COVID-19 Patients Admitted in a Tertiary Care Hospital in the Dominican Republic
De Luna et al., medRxiv, doi:10.1101/2020.12.11.20247437 (Preprint)
De Luna et al., Clinical and Demographic Characteristics of COVID-19 Patients Admitted in a Tertiary Care Hospital in the.., medRxiv, doi:10.1101/2020.12.11.20247437 (Preprint)
Dec 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 150 patients in the Dominican Republic, 132 treated with HCQ, showing higher mortality with treatment in unadjusted results. Confounding by indication is likely. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details; substantial unadjusted confounding by indication likely.
risk of death, 104.5% higher, RR 2.05, p = 0.69, treatment 15 of 132 (11.4%), control 1 of 18 (5.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
De Luna et al., 14 Dec 2020, retrospective, Dominican Republic, preprint, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.12.11.20247437; this version posted December 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Clinical and Demographic Characteristics of COVID-19 Patients Admitted in a Tertiary Care Hospital in the Dominican Republic Authors: David De Luna1, Yori Roque1, Nicolás Batlle1, Katherine Gómez1, Miguelina Jáquez1, Brinia Cabrera1, Lissa de la Cruz1, Osvaldo,Tavárez1, Rossy Belliard1, José Javier Sanchez2 Affiliations: 1 HOMS - COVID Study Team, Hospital Metropolitano de Santiago, Santiago de los Caballeros, Dominican Republic 2 Pontificia Universidad Católica Madre y Maestra, Santiago de los Caballeros, Dominican Republic Abstract To present clinical and demographic characteristics of COVID-19 patients admitted to Hospital Metropolitano de Santiago in Dominican Republic, we analyzed electronic medical records of all hospitalized patients clinically admitted as viral pneumonia through March - April, 2020. Of 374 patients, 150 (40.1%) laboratory confirmed, were included in this study. Most of the patients were men (104 / 69.3%) with a median (IQR 44 - 66) age of 54. Hypertension (83 / 55.3%) and diabetes mellitus (49 / 32.7%) were the most common comorbidities, whereas fever (120 / 80%), cough (79 / 52.7%) and fatigue (60 / 40%) were the most common presenting symptoms. 28 (18.7%) patients required admission to the intensive care unit, of them, 26 patients (17.3%) required mechanical ventilation. The overall mortality rate was 10.7% Higher levels of inflammatory markers were associated with longer length of stay (LOS). This findings indulge information that could contribute to stratify patients at higher risk of complications. Background By the end of 2019, the world began to confront numerous cases of viral pneumonia, initially detected in Wuhan, China, which quickly spread all around the globe, becoming a pandemic.1 Since its naming and further description, much is known about SARS-CoV-2 and its associated disease, COVID - 19, allowing health personnel a better understanding of its dynamics and outcomes. To date, almost a year after these first cases, more than 70 million people have been affected, and more thank 1,5 million have died.2 Recently, several drugs have demonstrated beneficial effects in COVID-19, including antivirals that can reduce viral replication and lessens the length of stay, but none have been able to prevent new infections or act as post exposure prophylactic agent. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.11.20247437; this version posted December 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . The Dominican Republic (DR) has been struggling with COVID-19 since the first confirmed case back in March 2020, in an italian tourist in the northern part of the country. By then, the country was in the middle of an electoral process, which is believed contributed to the rapid propagation and community transmission of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit